Peptides DB
Research-centric peptide and protocol reference hub
Study 16 of 17Thymosin Alpha-1 literatureNature medicineTop journal2018

Reply to 'F508del-CFTR is not corrected by thymosin α1'.

Not reported in abstract.

Read at Nature medicineAdd to compare

Where it sits

this study against the rest of the thymosin alpha-1 corpus
2
Preclinical · this one
12
Observational
0
Open-label
2
Randomised
1
Reviews

Summary and findings

This paper addresses the effect of thymosin alpha-1 on F508del-CFTR correction. The study critiques previous claims regarding the efficacy of thymosin alpha-1 in correcting the F508del mutation in cystic fibrosis. No specific numeric outcomes are reported in the abstract.

How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2018

Background

The study investigates the role of thymosin alpha-1 in correcting the F508del mutation in cystic fibrosis, a condition known to be caused by mutations in the CFTR gene. Prior research suggested potential benefits of thymosin alpha-1 in this context, making this critique relevant for understanding its true efficacy. This study is important as it challenges previous assertions and seeks to clarify the role of thymosin alpha-1 in cystic fibrosis treatment.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Thymosin Alpha-1 corpus

BThymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency in vitro.Virulence · 2026 · Intracellular p24 levels in CD4+ T cells decreased significantly, p=0.002.HumanBF508del-CFTR is not corrected by thymosin α1.Nature medicine · 2018In vitroAThe efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025 · 28-day all-cause mortality: 23.4% (127/542) in thymosin α1 group vs 24.1% (132/547) in placebo group, hazard ratio 0.99, 95% CI 0.77 to 1.27, P=0.93.HumanBProximal tubule reabsorptive dysfunction and risk of cardiovascular death among community-living adults: the HUNT-3 cohort.europepmc · 2026 · 1-SD higher urine A1M associated with HR 1.33 (95% CI 1.12-1.58) for cardiovascular death.HumanBPrecision biomarker discovery in hypertension through explainable AI and proteomics.europepmc · 2026 · AUROC = 0.7985 for CatBoost classifier.HumanBExploration and optimization of a respiratory outpatient triage model during the X disease epidemic: A retrospective observational study.europepmc · 2026 · Mean daily patient throughput of 550.43 (SD ± 284.13) individuals.Human